Coeptis Therapeutics Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ZSQR$2.79-17.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
| Three Months Ended | Six Months Ended | |||
|---|---|---|---|---|
| June 30, 2025 | June 30, 2024 | June 30, 2025 | June 30, 2024 | |
| SALES | ||||
| Sales | $200,681 | $– | $263,555 | $– |
| Total sales | 200,681 | – | 263,555 | – |
| Cost of goods | 45,157 | – | 90,313 | – |
| Gross profit | 155,524 | – | 173,242 | – |
| COST OF OPERATIONS | ||||
| Research and development expense | 290,309 | 398,817 | 376,968 | 1,175,886 |
| Salary expense | 442,785 | 459,099 | 881,958 | 904,458 |
| Amortization expense | 250,000 | 250,000 | 500,000 | 500,000 |
| Professional services expense | 2,975,620 | 864,588 | 5,301,187 | 2,045,087 |
| Stock based compensation expense | 191,021 | 611,570 | 788,752 | 708,459 |
| General and administrative expenses | 527,003 | 239,028 | 797,575 | 411,595 |
| Selling and marketing expense | – | 5,000 | 105,000 | 5,000 |
| Total cost of operations | 4,676,738 | 2,828,102 | 8,751,440 | 5,750,485 |
| LOSS FROM OPERATIONS | (4,521,214) | (2,828,102) | (8,578,198) | (5,750,485) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (67,788) | (66,056) | (139,279) | (266,561) |
| Other (expense) income, net | (338,460) | 8,063 | (227,046) | 94,688 |
| Unrealized gain on marketable securities | 390,566 | – | 390,566 | – |
| Change in fair value of derivative liabilities | 202,310 | (149,250) | 798,430 | (114,375) |
| TOTAL OTHER INCOME (EXPENSE), net | 186,628 | (207,243) | 822,671 | (286,248) |
| LOSS BEFORE INCOME TAXES | $(4,334,586) | $(3,035,345) | $(7,755,527) | $(6,036,733) |
| PROVISION FOR INCOME TAXES (BENEFIT) | $– | $– | $– | $– |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | (3,534,595) | (3,035,345) | (6,592,325) | (6,036,733) |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS | (799,991) | – | (1,163,202) | – |
| NET LOSS | $(4,334,586) | $(3,035,345) | $(7,755,527) | $(6,036,733) |
| LOSS PER SHARE | ||||
| Loss per share, basic and fully diluted | $(1.17) | $(0.08) | $(2.29) | $(0.17) |
| Weighted average number of common shares outstanding | 3,706,795 | 37,569,312 | 3,391,685 | 36,551,418 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.